This prospective cohort study evaluated 4,376 men diagnosed with clinically localized prostate cancer between 1997 and 2002, assessing the impact of BMI at diagnosis and subsequent weight changes on disease progression and mortality. Over the follow-up period, 14.6% experienced disease progression, 10.3% died from any cause, and 3.1% died from
